5.13 (-%)
As of Nov 21, 2024
Source:
Outlook Therapeutics, Inc is a biopharmaceutical company working to launch the first ophthalmic formulation of bevacizumab approved by the U.S. Food and Drug Administration, or the FDA, for use in retinal indications.
Country | United States |
Headquarters | iselin, new jersey |
Phone Number | (609) 619-3990 |
Industry | manufacturing |
CEO | C. Russell Trenary Iii |
Website | www.outlooktherapeutics.com |